Suchergebnisse - "Hasegawa, Yoshitaka"

PubPharm (39)

1

Structure-based lead optimization to improve potency and selectivity of a novel tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid series of heparanase-1 inhibitor

enthalten in: Bioorganic & medicinal chemistry | 2023

von Imai, Y. | Suzuki, R. | Wakasugi, D. | +16

2

Renoprotective Effect of TP0472993, a Novel and Selective 20-Hydroxyeicosatetraenoic Acid Synthesis Inhibitor, in Mouse Models of Renal Fibrosis

enthalten in: The Journal of pharmacology and experimental therapeutics | 2023

von Hirata, T. | Ohara, H. | Kojima, N. | +4

3

Receptor for Hyaluronic Acid-mediated Motility (RHAMM) Is Associated With Prostate Cancer Migration and Poor Prognosis

enthalten in: Cancer genomics & proteomics | 2023

von Minato, A. | Kudo, Y. | Noguchi, H. | +5

4

Effect of a Family Pharmacist System on Medication Adherence of Patients with Dyslipidemia during a COVID-19 Epidemic

enthalten in: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan | 2023

von Maeda, M. | Hasegawa, Y. | Tsukioka, R. | +1

5

Discovery of Novel Pyrazolylpyridine Derivatives for 20-Hydroxyeicosatetraenoic Acid Synthase Inhibitors with Selective CYP4A11/4F2 Inhibition

enthalten in: Journal of medicinal chemistry | 2022

von Kawamura, M. | Kobashi, Y. | Tanaka, H. | +14

6

Prognostic Value of Squamous Differentiation in Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy

enthalten in: Anticancer research | 2022

von Minato, A. | Noguchi, H. | Kimuro, R. | +6

7

Evaluation of the Extent of Variant Histology in Urothelial Carcinoma as a Predictive Marker of Clinical Outcomes After Radical Cystectomy

enthalten in: Cancer diagnosis & prognosis | 2021

von Minato, A. | Noguchi, H. | Moriya, R. | +6

8

LIQUID COMPOSITION FOR ENCAPSULATION AND ENCAPSULATED FORMULATION

enthalten in: Europäisches Patentamt | 2020

von HASHIMOTO TOMOYUKI | ONO MITSUAKI | HASEGAWA YOSHITAKA

9

CORE/SHELL Ln COMPLEX NANOPARTICLE

enthalten in: Europäisches Patentamt | 2018

von HASEGAWA YOSHITAKA | NIHEI AYUMI

10

Recommendation to Exclude Bile-Duct-Cannulated Rats with Hyperbilirubinemia for Proper Conduct of Biliary Drug Excretion Studies

enthalten in: Drug metabolism and disposition: the biological fate of chemicals | 2016

von Kato, K. | Hasegawa, Y. | Iwata, K. | +5